Semaglutide vs Tirzepatide
Both Semaglutide and Tirzepatide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Semaglutide
Evidence A+Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
View full Semaglutide profile →Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →Side-by-Side
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Evidence Grade | A+ | A+ |
| FDA Status | FDA-approved for weight management and type 2 diabetes | FDA-approved for weight management and type 2 diabetes |
| Typical Dose | 0.25–2.4 mg weekly (subcutaneous injection) | 2.5–15 mg weekly (subcutaneous injection) |
| Clinics Indexed | 2,285 | 1,850 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Semaglutide
- ✓Significant weight loss
- ✓Appetite suppression
- ✓Blood sugar control
- ✓Cardiovascular benefit
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.